PAS
MRNA icon

Park Avenue Securities’s Moderna MRNA Stock Holding History

Park Avenue Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,811
Closed -$334K – 1427
2024
Q2 		$334K Buy
2,811
+266
+10% +$33.7K ﹤0.01% 1146
2024
Q1 		$271K Sell
2,545
-1,160
-31% -$117K ﹤0.01% 1210
2023
Q4 		$368K Sell
3,705
-1,770
-32% -$149K 0.01% 1035
2023
Q3 		$566K Buy
+5,475
New +$611K 0.01% 791
2023
Q1 		– Sell
-7,535
Closed -$1.35M – 997
2022
Q4 		$1.35M Buy
7,535
+1,314
+21% +$215K 0.02% 401
2022
Q3 		$736K Buy
6,221
+2,976
+92% +$452K 0.01% 582
2022
Q2 		$464K Buy
3,245
+808
+33% +$115K 0.01% 739
2022
Q1 		$420K Buy
2,437
+381
+19% +$64.1K 0.01% 817
2021
Q4 		$522K Buy
2,056
+166
+9% +$48.5K 0.01% 692
2021
Q3 		$727K Buy
1,890
+757
+67% +$279K 0.01% 520
2021
Q2 		$266K Buy
+1,133
New +$202K 0.01% 890

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Park Avenue Securities's MRNA Position: Q3 2024 in Review

Park Avenue Securities sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,811 shares — an estimated $334K sold.

Park Avenue Securities first reported a position in MRNA in Q2 2021 and held it in 11 quarters. The position peaked at $1.35M in Q4 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Park Avenue Securities reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Park Avenue Securities sold 2,811 Moderna shares in Q3 2024, an estimated $334K.
  • Park Avenue Securities first reported a position in Moderna in Q2 2021 and held it in 11 quarters.
  • Park Avenue Securities's Moderna position peaked at $1.35M in Q4 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Park Avenue Securities's 13F filing for Q3 2024, filed 3 Oct 2024.